Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

Rapidly developing molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Epidermal growth factor receptor (EGFR) actively involves in modulation of various cancer
progression related mechanisms including angiogenesis, differentiation and migration …

Purpose Non-small cell lung cancer (NSCLC) accounts for about 85% in all cases of lung
cancer. In recent years, molecular targeting drugs for NSCLC have been developed rapidly …

To the Editor: To facilitate standardization and reveal inconsistencies in existing variant
annotations, we have designed a novel variant annotator, TransVar (http://www. transvar …

Kinases are involved in disease development and modulation of their activity can be
therapeutically beneficial. Drug-resistant mutant kinases are valuable tools in drug discovery …

Introduction EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of
lung adenocarcinoma. However, approximately 5% to 10% of patients with lung …